Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension.
Arterial hypertension is often part of a larger constellation of anthropometric and metabolic abnormalities that includes abdominal (or visceral) obesity, characteristic dyslipidemia (low high-density lipoprotein cholesterol and high triglycerides), glucose intolerance, insulin resistance and hyperuricemia. Using Adult Treatment Panel III criteria, prevalence is higher than in the general population and the metabolic syndrome (MS) can be found in as many as one third of patients. In hypertensives with MS, a high prevalence of hypertension-induced target organ damage and a negative prognostic value have been described. Dietary advice and life style changes should be strongly recommended and prompt pharmacologic treatment is required to control high blood pressure and to reduce risk. The effect of particular antihypertensive drugs on other components of the MS is an important clinical issue with consequences for the success of the treatment.
Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia, Spain. josep.redon@uv.es
Josep
J
Redon
Renata
R
Cífková
Krzysztof
K
Narkiewicz
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015897:Comorbidity; D005060:Europe / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology* / Q000517:prevention & control*; D024821:Metabolic Syndrome / Q000453:epidemiology*; D017410:Practice Guidelines as Topic; D015995:Prevalence; D040242:Risk Reduction Behavior; D012955:Societies, Medical
D000959:Antihypertensive Agents